Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyproheptadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 1.00 |
| ▸ | SETD7 | Q8WTS6 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyproheptadine SCHEMBL4021 | 1.00 | SETD7 (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Cyproheptadine SCHEMBL7923153 | 1.00 | SETD7 (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Cyproheptadine SCHEMBL30772122 | 0.98 | LMNA (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Cyproheptadine SCHEMBL11779784 | 0.98 | SETD7 (0.96) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Cyproheptadine SCHEMBL20610743 | 0.98 | LMNA (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Cyproheptadine SCHEMBL5500354 | 0.98 | LMNA (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Cyproheptadine SCHEMBL41842 | 0.98 | LMNA (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Cyproheptadine SCHEMBL29380652 | 0.98 | LMNA (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Cyproheptadine SCHEMBL9934753 | 0.96 | LMNA (0.97) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Cyproheptadine SCHEMBL3005524 | 0.96 | SETD7 (0.93) | SETD7CHRM2CHRM1ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3993811-B1 | THERAPEUTIC USES OF OXIDISING HYPOTONIC ACID SOLUTIONS | APPLIED PHARMA RES (CH) | 2025-02-26 | — | — | EP | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| EP-3801531-B1 | LOW GLYCEMIC GUMMY COMPOSITION AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2024-09-18 | — | — | EP | claimed |
| US-20240299292-A1 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2024-09-12 | — | — | US | claimed |
| EP-3641774-B1 | PECTIN GUMMY COMPOSITION AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2024-03-27 | — | — | EP | claimed |
| EP-3500686-B1 | METHODS FOR DETECTING CRANIOPHARYNGIOMA AND FOR SELECTING MEDICAMENTS AND PATIENTS FOR TREATMENT | QUEST DIAGNOSTICS INVEST LLC (US) | 2024-01-10 | — | — | EP | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-4255443-A1 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | Seattle Gummy Company (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| US-20220339166-A1 | POST COVID19 VACCINE REMEDIES | IPRX, LLC | 2022-10-27 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| WO-2022119954-A1 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2022-06-09 | — | — | WO | claimed |
| US-12633357-B2 | State-dependent fail bit count criteria for memory apparatus program performance gain | SanDisk Technologies, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125770-A1 | INFLAMMATORY DISORDER IN A FELIDAE | MARS, INCORPORATED (US) | 2026-05-07 | — | — | US | disclosed |
| US-12614598-B2 | Fake fast plane detection in early program termination | SanDisk Technologies, Inc. (US) | 2026-04-28 | — | — | US | disclosed |
| WO-2022026223-A1 | DELIVERY SYSTEM FOR AYAHUASCA-LIKE SUBSTANCES | ELLIS GREGORY (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220031966-A1 | Delivery System For Ayahuasca-Like Substances | MONSTER COLOR CARNIVAL LLC | 2022-02-03 | — | — | US | disclosed |
| US-11235110-B1 | Delivery system for ayahuasca-like substances | MONSTER COLOR CARNIVAL LLC | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12614598-B2 | Fake fast plane detection in early program termination | PTK2, CD69, TESK2 | HRH1 4284/4885SETD7 2634/4885CHRM2 1836/4885 |
| US-20220031966-A1 | Delivery System For Ayahuasca-Like Substances | DBH, CRH, PNMT | HRH1 764/4885SETD7 1653/4885CHRM2 1172/4885 |
| US-11235110-B1 | Delivery system for ayahuasca-like substances | DBH, CRH, PNMT | HRH1 764/4885SETD7 1653/4885CHRM2 1172/4885 |
| US-20260125770-A1 | INFLAMMATORY DISORDER IN A FELIDAE | FPR2, FPR1, FLAD1 | HRH1 908/4885SETD7 876/4885CHRM2 4238/4885 |
| US-12633357-B2 | State-dependent fail bit count criteria for memory apparatus program performance gain | CACNA2D4, CACNA2D2, BAG2 | HRH1 4048/4885SETD7 1174/4885CHRM2 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.